19:06 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...
18:27 , Nov 30, 2018 |  BC Week In Review  |  Company News

WuXi NextCode investing in genomic sequencing project in Ireland

WuXi NextCode Genomics Inc. (Cambridge, Mass.) unveiled plans to expand an Irish sequencing program by investing up to $400 million in its partner Genomics Medicine Ireland Ltd. (Dublin, Ireland), which it acquired in November. The...
15:49 , Nov 29, 2018 |  BC Extra  |  Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...
23:49 , Nov 27, 2018 |  BC Extra  |  Company News

WuXi NextCode investing in genomic sequencing project in Ireland

WuXi NextCode Genomics Inc. (Cambridge, Mass.) unveiled plans to expand an Irish sequencing program by investing up to $400 million in its recently acquired partner, Genomics Medicine Ireland Ltd. (Dublin, Ireland). The investment aims to...
15:16 , Oct 26, 2018 |  BioCentury  |  Regulation

Learning the limits of limited use

While it’s too soon to tell if FDA’s limited-use pathway for anti-infectives will boost development in the underserved field, the pathway’s first approval has helped clarify the amount of uncertainty the agency is willing to...
18:08 , Oct 19, 2018 |  BC Week In Review  |  Company News

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1 billion in cash. The deal gives Novartis 177Lu-PSMA-617, a radioligand therapy in the Phase III VISION trial to treat prostate-specific membrane...
17:47 , Oct 18, 2018 |  BC Extra  |  Company News

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1 billion in cash. The deal gives Novartis 177Lu-PSMA-617, a radioligand therapy in the Phase III VISION trial to treat prostate-specific membrane...
22:19 , Oct 11, 2018 |  BC Innovations  |  Translation in Brief

Public funding highlights: 3Q18

Public funding highlights: 3Q18 Selected developments and initiatives in 3Q18 from major sources of public funding including NIH , the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes of Health...
18:39 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Altheia lands $11M series A

Altheia Science s.r.l. (Milan, Italy) closed an $11 million series A round. The round could be expanded by another $6.7 million with the participation of institutional investors, the company said. Paolo Rizzardi, Altheia's chairman and...
22:33 , Sep 24, 2018 |  BC Extra  |  Financial News

Altheia lands $11M series A

Altheia Science S.r.l. (Milan, Italy) closed an $11 million series A round. The round could be expanded by another $6.7 million with the participation of institutional investors, the company said. Paolo Rizzardi, Altheia's chairman and...